| 1. | Hbig hepatitis b immunoglobulin 乙型肝炎免疫球蛋白 |
| 2. | Clinical study on hbig interrupting hbv of mother - infant perpendicular dissemination 乙型肝炎免疫球蛋白阻断乙肝病毒母婴垂直传播临床研究 |
| 3. | Babies born to carrier mothers should receive an additional dose of hepatitis b immunoglobulin at birth 带病毒母亲产下的婴儿在出生时需注射多一针乙型肝炎免疫球蛋白。 |
| 4. | This may include an appropriate hepatitis b immunoglobulin administration strategy for high - risk infants and involve efforts to minimize noncompliance 将来的策略可能包括适当给高危儿使用乙型肝炎免疫球蛋白和努力将无效疫苗减到最少。 |
| 5. | For babies born to carrier mothers , an additional hepatitis b immunoglobulin is given within 24 hours of birth to prevent transmission of infection from their mothers 若婴儿的母亲为带菌者,婴儿须在出生后24小时内接受额外的乙型肝炎免疫球蛋白注射,以防止病毒经母亲传给婴儿。 |
| 6. | Conclusion : low - dose im hbig plus lamivudine provides safe and effective long - term prophylaxis against recurrent hbv at < 10 % the cost of the high - dose regimen 结论:低剂量肌注乙型肝炎免疫球蛋白联合拉米夫定的使用为长时间的预防hbv复发提供了安全有效的方案并且可使花费小于大剂量用药方案费用的10 % 。 |
| 7. | Methods : australian and new zealand patients who received low - dose hbig plus lamivudine following liver transplantation for hbv - related end - stage liver disease were studied 方法:选择澳洲和新西兰曾接受乙型肝炎免疫球蛋白联合拉米夫定的患者,对这类患者行肝移植后发生的与乙型肝炎病毒相关的末期肝脏疾病进行研究。 |